HomeCompareDM vs MRK

DM vs MRK: Dividend Comparison 2026

DM yields 40.32% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $30.3K in total portfolio value· pulled ahead in Year 5
10 years
DM
DM
● Live price
40.32%
Share price
$4.96
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.4K
Annual income
$5.49
Full DM calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — DM vs MRK

📍 MRK pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DM + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DM pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DM
Annual income on $10K today (after 15% tax)
$3,427.42/yr
After 10yr DRIP, annual income (after tax)
$4.67/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,592.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DM + MRK for your $10,000?

DM: 50%MRK: 50%
100% MRK50/50100% DM
Portfolio after 10yr
$42.6K
Annual income
$5,059.64/yr
Blended yield
11.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DM
Analyst Ratings
3
Buy
6
Hold
1
Sell
Consensus: Hold
Price Target
$5.25
+5.8% upside vs current
Range: $5.00 — $5.50
Altman Z
-12.2
Piotroski
3/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DM buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMMRK
Forward yield40.32%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$27.4K$57.7K
Annual income after 10y$5.49$10,113.78
Total dividends collected$4.5K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$5.25$128.54

Year-by-year: DM vs MRK ($10,000, DRIP)

YearDM PortfolioDM Income/yrMRK PortfolioMRK Income/yrGap
1$12,716$2,016.13$11,213$373.04+$1.5KDM
2$14,804$1,198.01$12,667$512.06+$2.1KDM
3$16,492$651.74$14,439$708.14+$2.1KDM
4$17,986$339.28$16,640$988.16+$1.3KDM
5← crossover$19,418$172.90$19,432$1,394.07$14.00MRK
6$20,864$87.23$23,057$1,992.90$2.2KMRK
7$22,369$43.80$27,889$2,894.79$5.5KMRK
8$23,957$21.94$34,518$4,286.29$10.6KMRK
9$25,644$10.98$43,912$6,494.35$18.3KMRK
10$27,445$5.49$57,714$10,113.78$30.3KMRK

DM vs MRK: Complete Analysis 2026

DMStock

Desktop Metal, Inc. engages in manufacture and sale of additive manufacturing technologies for engineers, designers, and manufacturers in the Americas, Europe, the Middle East, Africa, and the Asia- Pacific. The company offers Production System, an industrial manufacturing solution; Shop System, a mid-volume binder jetting platform; X-series platform for serial production binder jet 3D printed metal, ceramic, or composite parts, balancing speed, and quality; and Studio System, an office metal 3D printing system; and Fiber platform that offers a desktop 3D printer. In addition, it provides Xtreme 8K platform, designed for industrial, high-temperature production of end-use photopolymer parts, and uses high-powered light sources with a water-cooled DLP chip; Einstein series, designed for dental professionals which offers 3D printing; P4K platform offers series of advanced DLP printer models designed for volume production in precision applications; Envision One platform; which leverages patented CDLM technology for high-volume production of end-use photopolymer parts; D4K Pro platform, designed for jewelry and chairside settings; S-Max platform, which provides digital casting solution; and Robotic Additive Manufacturing, or RAM, platform that offers robotic 3D printing solutions. Further, the company offers S-Print, an entry-level solution for prototypes and small series production in digital casting applications; and 3D-Bioplotter platform which offers biofabrication solution. Additionally, the company provides binder jetting materials, DLP and CDLM photopolymer resins, BMD materials, micro-AFP materials, and bioprinting materials. It serves automotive, aerospace, healthcare and dental, consumer products, heavy industry, machine design, and research and development industries. The company was founded in 2015 and is headquartered in Burlington, Massachusetts.

Full DM Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DM vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DM vs SCHDDM vs JEPIDM vs ODM vs KODM vs MAINDM vs JNJDM vs ABBVDM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.